Switzerland Switzerland has long combined a world-class pharmaceutical ecosystem with rapid access to medical innovation, but mounting geopolitical and pricing pressures are putting that position to the test. Stuart Head, General Manager of Gilead Switzerland, explores what this changing environment means for patients and the industry, while outlining the opportunities emerging…
Hong Kong Hong Kong recently announced its first-ever Five-Year Plan, the latest sign of closer alignment with mainland China. With a clearer roadmap to 2030, what are the implications for biopharma? A First FYP Even since returning to Chinese control in 1997, Hong Kong has maintained its role as a trading…
USA The National Health Council represents nearly 200 member organizations, with patient groups required by its bylaws to hold the majority of governance and decision-making roles. Five years after taking the helm as CEO, Randall “Randy” Rutta oversees an association formed more than a century ago to ensure the patient experience…
Europe Michala Fischer-Hansen, EVP and Head of Europe & International Markets at Lundbeck, discusses her return to pharma and Lundbeck’s focused innovator strategy, centred on neuroscience, R&D and growth through regional partnerships. She examines Europe’s evolving pharmaceutical landscape, from patent expiries and pricing pressure to growing attention on brain health, and…
USA Joshua Salsi, Head of North America, Biocon Biologics explains the company’s evolution into an integrated, global biosimilars company following the 2022 Viatris portfolio reacquisition. He highlights the company’s growing US leadership, expanding pipeline, vertical integration, and focus on patient access. Salsi goes on to stresses that long-term biosimilar growth depends…
USA Access works when all pieces are in place. Hearing directly from patients about what diagnosis or how a treatment impacts their lives is meaningful to everyone involved Scott Weintraub, Head of US Business at Alexion, AstraZeneca Rare Disease, discusses how his experience across commercial leadership, strategy, and rare disease innovation…
USA Keren Haruvi, President of Sandoz North America, reflects on the company’s transformation following its spin-off from Novartis and outlines how Sandoz is positioning itself at the forefront of the evolving US generics and biosimilars landscape. She discusses the structural barriers shaping market access, from PBM dynamics to patent complexity, while…
Europe Europe is rewriting the rules governing medicines, innovation, and industrial competitiveness, with consequences that reach far beyond regulation alone. Pricing pressure from the United States, slower market access, rising administrative complexity, and the global race for biotech leadership are forcing policymakers to decide whether the region will remain a premier…
USA Just over one year into the second Trump administration, the US healthcare and life science market is navigating a steady stream of series of unprecedented policy shifts. Long defined by patients in the US having more innovative medicines available to them than anywhere else on earth, but the market’s long-criticized…
USA Paul Kim, a leading FDA attorney and policy expert formerly at both the FDA and the US Congress, discusses the current shifts within the American life sciences and regulatory landscape. Kim examines the prevailing sentiment of the industry amidst a period of significant structural upheaval and regulatory whiplash. He offers…
USA Christine Baeder, President of USA and LATAM at Apotex, discusses the company’s evolution following private equity investment, its Generics Plus strategy, and the critical role of the US market. She highlights supply chain resilience, the challenges facing biosimilar adoption, and the need for structural policy reforms to sustain affordability, innovation…
Hong Kong Hong Kong is at a strategic inflection point as it seeks to redefine its role in global life sciences through regulatory credibility, institutional design, and long-term positioning between China and international markets. Industry stalwart Lo Yuk Lam reflects on how regulation, talent, capital markets, and national planning intersect to shape…
See our Cookie Privacy Policy Here